Insider Selling: Ophthotech Corp (NASDAQ:OPHT) Insider Sells 3,798 Shares of Stock
Ophthotech Corp (NASDAQ:OPHT) insider David R. Guyer sold 3,798 shares of the stock in a transaction on Friday, January 5th. The shares were sold at an average price of $3.17, for a total transaction of $12,039.66. Following the sale, the insider now directly owns 42,458 shares of the company’s stock, valued at approximately $134,591.86. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Shares of Ophthotech Corp (OPHT) opened at $3.17 on Tuesday. Ophthotech Corp has a 12 month low of $2.24 and a 12 month high of $4.86. The company has a market cap of $114.24, a P/E ratio of 2.03 and a beta of 1.58.
Ophthotech (NASDAQ:OPHT) last announced its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported $5.25 EPS for the quarter, topping analysts’ consensus estimates of $4.38 by $0.87. Ophthotech had a net margin of 26.69% and a negative return on equity of 69.40%. equities analysts expect that Ophthotech Corp will post 2.88 EPS for the current fiscal year.
Several equities research analysts have recently commented on the stock. ValuEngine cut shares of Ophthotech from a “buy” rating to a “hold” rating in a research report on Sunday, December 31st. TheStreet raised shares of Ophthotech from an “e+” rating to a “c” rating in a research report on Thursday, November 30th. Finally, Zacks Investment Research upgraded shares of Ophthotech from a “hold” rating to a “strong-buy” rating and set a $3.25 price objective for the company in a research note on Monday, November 13th.
COPYRIGHT VIOLATION NOTICE: “Insider Selling: Ophthotech Corp (NASDAQ:OPHT) Insider Sells 3,798 Shares of Stock” was posted by Marea Informative and is owned by of Marea Informative. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.mareainformativa.com/2018/01/30/david-r-guyer-sells-3798-shares-of-ophthotech-corp-opht-stock-updated-updated-updated.html.
Ophthotech Corporation is a biopharmaceutical company. The Company is engaged in the development of therapeutics to treat ophthalmic diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the retina, known as the macula, that may result in blindness.
Receive News & Ratings for Ophthotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ophthotech and related companies with MarketBeat.com's FREE daily email newsletter.